It has been shown that γδ T cells are an important source of interleukin 17 (IL-17) during a variety of infections and autoimmune diseases [1] [2] [3] [4] [5] [6] [7] [8] . These 'innate-like' IL-17-committed γδ T cells (γδT17 cells) are present in lymph nodes as well as peripheral tissues, including the dermis, lungs and peritoneal cavity [2] [3] [4] [5] [6] . The γδT17 cells express many of the hallmarks of αβ T cells of the T H 17 subset of helper T cells, including the chemokine receptor CCR6, the transcription factor RORγt and the IL-23 receptor (IL-23R) 2,9 . However, unlike T H 17 cells, γδT17 cells differentiate into IL-17-commited cells in the thymus and emerge as effector cells able to produce IL-17 rapidly after stimulation via the T cell antigen receptor (TCR) and/or exposure to IL-23 and IL-1β 2,9 . The γδT17 cells consist of V γ 4 + and V γ 6 + subsets 10 . V γ 6 + γδT17 cells express the invariant TCR V γ 6V δ 1 (γ-chain variable region 6 and δ-chain variable region 1) and develop in the late embryonic thymus, subsequent to V γ 5V δ 1-expressing dendritic epidermal γδ T cell precursors 11, 12 . V γ 4 + γδT17 cells are characterized by a more diverse TCR repertoire and expression of the scavenger receptor SCART2 (ref. 13). It has been suggested that these cells develop predominantly in a late embryonic time window 14 . Whether V γ 4 + and V γ 6 + subsets of γδT17 cells have distinct functions has been unclear.
A r t i c l e s
It has been shown that γδ T cells are an important source of interleukin 17 (IL-17) during a variety of infections and autoimmune diseases [1] [2] [3] [4] [5] [6] [7] [8] . These 'innate-like' IL-17-committed γδ T cells (γδT17 cells) are present in lymph nodes as well as peripheral tissues, including the dermis, lungs and peritoneal cavity [2] [3] [4] [5] [6] . The γδT17 cells express many of the hallmarks of αβ T cells of the T H 17 subset of helper T cells, including the chemokine receptor CCR6, the transcription factor RORγt and the IL-23 receptor (IL-23R) 2,9 . However, unlike T H 17 cells, γδT17 cells differentiate into IL-17-commited cells in the thymus and emerge as effector cells able to produce IL-17 rapidly after stimulation via the T cell antigen receptor (TCR) and/or exposure to IL-23 and IL-1β 2, 9 . The γδT17 cells consist of V γ 4 + and V γ 6 + subsets 10 . V γ 6 + γδT17 cells express the invariant TCR V γ 6V δ 1 (γ-chain variable region 6 and δ-chain variable region 1) and develop in the late embryonic thymus, subsequent to V γ 5V δ 1-expressing dendritic epidermal γδ T cell precursors 11, 12 . V γ 4 + γδT17 cells are characterized by a more diverse TCR repertoire and expression of the scavenger receptor SCART2 (ref. 13) . It has been suggested that these cells develop predominantly in a late embryonic time window 14 . Whether V γ 4 + and V γ 6 + subsets of γδT17 cells have distinct functions has been unclear.
Despite the increasing evidence that γδ T cells participate in many diseases, understanding of the factors that control their development lags behind that of αβ T cells. Developing γδ T cells show enrichment for the transcription factor Sox13 (of the sry-related high-mobility group box family), and Sox13 has been suggested to serve a general role in γδ T cell differentiation 15 . Transgenic mice overexpressing Sox13 are characterized by a lower abundance of αβ T lineagecommitted CD4 + CD8 + double-positive thymocytes, whereas γδ T cell development remains normal 15 . In contrast, mice at embryonic day 18.5 that have targeted deletion of Sox13 are characterized by approximately 70% fewer total γδ thymocytes 15 . Those Sox13-deficient mice are reported to have severe postnatal growth abnormalities 15 that preclude study of how Sox13 deficiency affects γδ T cell subsets in adult mice. Subsequently, developing γδT17 cells were shown to have enrichment for Sox13, although whether Sox13 is required in vivo for their generation or function has not been reported 16, 17 .
The dynamics of the trafficking of γδ T cells in peripheral tissues is also less well characterized than that of αβ T cells. The γδT17 cells are present in both the dermis and in skin draining lymph nodes, but it has been unclear whether the dermal cells traffic to lymph nodes. It is also not known whether, after activation in lymph nodes, γδT17 cells are able to home to sites of inflammation.
Here we found that the V γ 4 + subset of γδT17 cells matured in the neonatal thymus in a Sox13-dependent manner. Sox13-mutant mice were protected from psoriasis-like dermatitis, which linked V γ 4 + γδT17 cells to this inflammatory skin condition. We also found that γδT17 cells migrated from inflamed skin to draining lymph nodes, underwent substantial population expansion in responding lymph nodes and homed from lymph nodes back to skin. We suggest that recirculation of expanded γδT17 cell populations may contribute to the systemic exacerbations in psoriasis that can occur after local application of imiquimod in humans.
A r t i c l e s RESULTS B6.SJL/NCI and B6.SJL/Tac mice lack V g 4 + gdT17 cells During experiments with CD45.2 + C57BL/6N (B6/NCI) and congenic CD45.1 + (B6.SJL/NCI) strains from the US National Cancer Institute (NCI), we observed that suspensions of lymph node cells obtained from B6.SJL/NCI mice had considerably fewer V γ 4 + CCR6 + γδ T cells than did those from B6/NCI mice (Fig. 1a,b) . CCR6 + γδ T cells correspond to a population of γδT17 cells 18 . Consistent with the lack of V γ 4 + CCR6 + γδT17 cells in B6.SJL/NCI mice, there were considerably fewer V γ 4 + γδ T cells expressing IL-17A in the lymph nodes after stimulation with the phorbol ester PMA plus ionomycin (Fig. 1c,d ). In contrast, both strains had a similar number of V γ 4 − γδ T cells, αβ T cells and non-T cells expressing IL-17A in the lymph nodes (Fig. 1c,d) .
Consistent with a published report 13 , V γ 4 + CCR6 + γδT17 cells in the lymph nodes expressed the scavenger receptor SCART2, but their V γ 4 − counterparts did not (Supplementary Fig. 1a) . SCART2 was also expressed by a subset of IL-7Rα hi CCR6 + non-γδT cells in the lymph node, a population that is also IL-17 committed 19, 20 ( Supplementary Fig. 1c ). V γ 4 + SCART2 + CCR6 + γδT17 cells were nearly completely absent from lymph nodes from B6.SJL/NCI mice, whereas the frequency of SCART2 + IL-7Rα hi CCR6 + non-γδ T cells was unchanged in B6.SJL/NCI mice relative to that in B6/NCI mice ( Supplementary Fig. 1a,c,e) .
SCART2 expression by dermal TCRγδ int cells has also been reported 13 ; we found that SCART2 expression marked the V γ 4 + CCR6 + subset (Supplementary Fig. 1b) . Staining for V γ 4 on CCR6 + TCRγδ int cells was weak when we used dispase digestion to separate epidermal and dermal ear-skin sheets (Supplementary Fig. 1b) , which suggested that the V γ 4 epitope was sensitive to dispase. Therefore, we used staining for SCART2 to define V γ 4 + γδT17 cells in dermal-cell suspensions prepared with dispase, whereas we used staining for V γ 4 in whole-ear skin-cell suspensions prepared without dispase.
Consistent with observations obtained with lymph nodes, we observed considerably fewer SCART2 + CCR6 + γδT17 cells in dermal-cell suspensions, whereas the abundance of SCART2 − CCR6 + γδT17 cells ( Fig. 1e and Supplementary Fig. 1b ) and SCART2 + IL-7Rα hi CCR6 + non-γδ T cells (Supplementary Fig. 1d,f) was unchanged in B6.SJL/ NCI mice relative to that in B6/NCI mice. We observed a similar lack of V γ 4 + CCR6 + γδT17 cells in the spleen, peritoneal cavity and lungs, whereas CCR6 − γδ T cells were present at normal frequencies ( Supplementary Fig. 2a-d) . Together these data suggested that the production of SCART2 + V γ 4 + γδT17 cells was specifically impaired in B6.SJL/NCI mice.
To explore the nature of the defect noted above, we investigated whether V γ 4 + γδT17 cells were present in other substrains. CD45.1 + congenic C57BL/6 mice were generated by backcrossing the allele encoding CD45.1 expressed by SJL mice onto the C57BL/6 background (Boyse laboratory) 21 . The National Cancer Institute (NCI), as well as The Jackson Laboratory (Jax), Taconic Farms (Tac) and Charles River Laboratories (CR) maintain colonies of this strain (called 'B6.SJL/NCI' , 'B6.SJL/Jax' , 'B6.SJL/Tac' and 'B6.SJL/CR' , respectively, here). V γ 4 + CCR6 + γδT17 cells were present at normal frequencies in SJL mice (Fig. 1f) , which suggested that genetic polymorphisms in SJL mice probably did not contribute to the defect in B6.SJL/NCI mice. The B6.SJL strain maintained at NCI was exported from the Boyse laboratory to the Mathieson laboratory at the NIH in the 1970s and to NCI in the 1980s. Tac received the strain from NCI in 1995 and 'refreshed' their colony from NCI stock in 2007. Jax imported the strain from the Boyse laboratory in 1990; CR USA received this strain from CR France in 2010. Like B6.SJL/NCI mice, B6.SJL/Tac mice were characterized by a deficiency in V γ 4 + CCR6 + γδT17 cells, whereas the frequency of these cells was normal in B6.SJL/Jax and B6.SJL/CR mice (Fig. 1f) . These data suggested that a spontaneous mutation became fixed in the B6.SJL/NCI colony before 2007 (when Tac 'refreshed' their colony from NCI stock). 
A spontaneous Sox13 mutation causes loss of V g 4 + gdT17 cells When we intercrossed B6/NCI and B6.SJL/NCI mice, we found that the F 1 offspring had a normal frequency of V γ 4 + CCR6 + γδT17 cells in the lymph nodes (Fig. 2a) , which suggested that the B6.SJL/NCI trait was recessive. Analysis of 121 F 2 offspring obtained by intercrossing of the F 1 mice showed that 94 mice (~78%) had a normal frequency of V γ 4 + CCR6 + γδT17 cells in the lymph nodes, whereas 27 mice (~22%) had a lower frequency of these cells (Fig. 2a) . Moreover, the B6.SJL/NCI trait was tightly linked to the Ptprc locus (which encodes the congenic marker CD45), although genetic complementation with CD45-deficient mice suggested that the mutation was not in Ptprc itself (Fig. 2b,c) . On the basis of results obtained with 27 F 2 mice (54 meioses and 3 recombination events; Fig. 2c ) and additional analysis of 95 offspring from F 1 mice backcrossed to B6.SJL/NCI mice (95 meioses and 0 recombination events), we calculated a linkage distance of 2 cM (3 recombination events among 149 total meioses). These data suggested the B6.SJL/NCI trait was controlled by a single locus located within approximately 2 cM of Ptprc.
Whole-exome sequencing of B6.SJL/NCI mouse DNA and comparison to the reference B6 genome sequence identified 86 nonsynonymous coding variants in genes located within 3 cM of Ptprc. We ruled out 84 of those variants, as they were present in mouse strains that have V γ 4 + CCR6 + γδT17 cells (Supplementary Fig. 3a,b and Supplementary Tables 1 and 2 ). We were unable to confirm one coding variant by Sanger sequencing and excluded it. The one coding variant that remained (Supplementary Table 2 ) was a single insertion of a cytosine nucleotide at codon 330 in Sox13 (c.987_988insC; Ensembl transcript identifier, ENSMUST00000094551) that resulted in a premature stop codon nine amino acids downstream (p.S330QfsX9; Fig. 3a,b) . The stop codon was upstream of the DNA-binding high-mobility-group domain but was downstream of the leucinezipper and glutamine-rich region 22, 23 . We confirmed by Sanger sequencing that this mutation was present in B6.SJL/NCI and B6.SJL/ Tac mice but was absent from B6.SJL/Jax and B6.SJL/CR mice.
To explore whether the mutation affected the abundance of Sox13 mRNA, we sorted V γ 4 + and V γ 4 − CD24 hi γδ thymocytes and measured Sox13 transcripts by real-time PCR with primers spanning exons 1-2, 6-7 and 12-13. Sox13 transcripts were more abundant in wild-type V γ 4 + CD24 hi γδ T thymocytes than in V γ 4 − CD24 hi γδ T thymocytes ( Fig. 3c) , consistent with published data 17 . Notably, Sox13 transcripts were ~85% less abundant in V γ 4 + CD24 hi γδ T cells from B6.SJL/NCI mice than in those from B6/NCI mice ( Fig. 3c) , probably because of the induction of nonsense-mediated decay by the premature stop codon 24 . Thus, B6.SJL/NCI mice had a spontaneous Sox13 mutation that introduced a stop codon in the middle of the open reading frame; we call this disrupted allele 'Sox13 mut ' here.
Sox13 intrinsically regulates the development of V g 4 + gdT17 cells Next we determined whether the defect in Sox13 mut/mut (B6.SJL/NCI) mice was intrinsic to hematopoietic cells. It has been shown that γδT17 cells are produced in an early wave in the embryonic and neonatal A r t i c l e s thymus and are poorly reconstituted by bone marrow transferred into irradiated wild-type mice 14, 19, 25 . We have noted poor reconstitution of γδT17 cells by bone marrow in irradiated TCRδ-deficient recipients except with cotransfer of neonatal thymocytes 19 . Here, although we continued to find that neonatal thymocytes provided the most efficient reconstitution (data not shown), transfer of wildtype bone marrow into irradiated TCRδ-deficient mice was sufficient to reconstitute V γ 4 + CCR6 + γδT17 cells when we waited at least 12 weeks (Fig. 4a,b) . The basis for the difference in reconstitution efficiency in various studies is unclear. Notably, however, bone marrow from Sox13 mut/mut mice did not reconstitute V γ 4 + CCR6 + γδT17 cells in irradiated TCRδ-deficient hosts (Fig. 4a,b) .
CCR6 − γδ T cells from the lymph nodes, which are not IL-17 committed and include mainly V γ 4 + and V γ 1 + cell subsets ( Supplementary  Fig. 4a,b) , are efficiently reconstituted by bone marrow transfer 14 , and reconstitution was unaffected by the Sox13 mutation (Fig. 4a,b) . Fig. 4a,b) that develop in the late embryonic period 11, 12 , were not reconstituted by bone marrow transplantation (Fig. 4a,b) . This may reflect a strong requirement for the embryonic thymus for the development of V γ 6 + γδT17 cells 14 .
We also examined the corresponding cells in the ear skin dermis, using SCART2 to identify the V γ 4 + subset of γδT17 cells. We observed reconstitution of SCART2 + CCR6 + γδT17 cells after transfer of bone marrow cells from wild-type mice but not after transfer of bone marrow cells from Sox13 mut/mut mice (Fig. 4b) . SCART2 − CCR6 + γδT17 cells were not reconstituted by bone marrow from either source (data not shown), consistent with the data obtained with lymph nodes.
To determine whether the defect in Sox13 mut/mut mice was intrinsic to γδT17 cells, we reconstituted irradiated TCRδ-deficient mice with a mixture of CD45.2 + wild-type bone marrow plus either CD45.1 + wild-type bone marrow or CD45.1 + Sox13 mut/mut bone marrow. Whereas V γ 4 + CCR6 − γδ T cells were reconstituted in this mixed setting by bone marrow from either source, Sox13 mut/mut bone marrow did not reconstitute lymph node V γ 4 + CCR6 + γδT17 cells or SCART2 + CCR6 + γδT17 dermal cells (Fig. 4c) . Together these data suggested that a cell-intrinsic defect in Sox13 mut/mut mice selectively blocked the development of V γ 4 + γδT17 cells.
Impaired maturation of V g 4 + gdT17 cells in neonatal thymus
Given that Sox13 mut/mut (B6.SJL/NCI) mice lacked V γ 4 + CCR6 + γδT17 cells in all tissues examined, we sought to determine whether their development in the neonatal thymus 19, 26 was blocked. Sox13 mut/mut neonates at day 0 after birth had V γ 4 + γδT17 cells that were CD24 hi CCR6 − (Fig. 5a) , indicative of an immature phenotype. At day 5, more V γ 4 + γδT17 cells were present, and approximately 20-30% had a mature CD24 lo CCR6 + phenotype (Fig. 5a) . Sox13 mut/mut neonates had fewer V γ 4 + γδT17 cells than Sox13 mut/+ neonates had, and they did not achieve a CD24 lo CCR6 + phenotype (Fig. 5a,b) , which suggested that their maturation was blocked.
In contrast, V γ 4 − γδT17 cells were more abundant and many had a mature CCR6 + CD24 lo phenotype in neonates at day 0; by day 5, nearly all were CCR6 + CD24 lo mature cells (Fig. 5c) . Consistent with the normal number of V γ 4 − γδT17 cells in the periphery (Fig. 1) , Sox13 mut/mut neonates had only slightly fewer V γ 4 − γδT17 thymocytes than Sox13 mut/+ neonates had (Fig. 5d) , and their maturation into CCR6 + CD24 lo cells remained intact. Sox13 mut/mut V γ 4 − γδT17 cells also expressed normal amounts of IL-7Rα, which is abundant on γδT17 cells 19, 27 (Supplementary Fig. 5a ). However, the abundance of γδ TCRs on the surface of V γ 4 − γδT17 cells from Sox13 mut/mut neonates was ~30% lower than that on cells from Sox13 mut/+ neonates, whereas the abundance on CCR6 − γδ T cells was unaltered (Supplementary Fig. 5b,c) . These data suggested that V γ 4 − γδT17 
d.) or four experiments with nine mice (f).
A r t i c l e s cells developed before V γ 4 + γδT17 cells and were less dependent on Sox13 for their development.
B6.SJL/NCI mice are protected from psoriasis-like dermatitis
Dermal γδT17 cells have been suggested to promote psoriasis-like dermatitis [4] [5] [6] . We sought to determine whether Sox13 mut/mut (B6.SJL/ NCI) mice, which selectively lacked V γ 4 + γδT17 cells, were protected from psoriasis-like changes. Daily application of 5% imiquimod cream to the ear skin led to an increase in ear thickness that was nearly 50% less in Sox13 mut/mut mice than in wild-type mice at day 5 (Fig. 6a) . Histological analysis of wild-type ear skin at day 5 showed the expected epidermal thickening (acanthosis) 28 and collections of neutrophils in the epidermis (Fig. 6b) . In contrast, ear skin from Sox13 mut/mut mice had less acanthosis and fewer epidermal neutrophil pustules (Fig. 6b) . Moreover, flow cytometry identified fewer Ly6G + CD11b + neutrophils in Sox13 mut/mut ear skin than in wild-type ear skin at day 3 and a trend toward fewer neutrophils at day 5 (Fig. 6c) . After 3 d of imiquimod treatment, Sox13 mut/mut ear skin had a lower abundance of transcripts encoding IL-17A and IL-17F than did wildtype ear skin (Fig. 6d) . To assess IL-17 production by dermal cells ex vivo, we digested whole ear skin in the presence of brefeldin A and stained cell suspensions for intracellular cytokines. We observed very little IL-17A in untreated wild-type ear skin; however, after 3 days of imiquimod treatment, V γ 4 + and V γ 4 − TCRγδ int cells produced IL-17A (Fig. 6e) . After 3 d of imiquimod treatment, we observed less IL-17A production by V γ 4 − TCRγδ int cells from Sox13 mut/mut ear skin than by those from wild-type ear skin (Fig. 6e) , which suggested that in addition to the deficiency in V γ 4 + γδT17 cells, the function of V γ 4 − γδT17 cells may not have been fully intact. Consistent with the diminished IL-17A production after 3 d of imiquimod treatment, Sox13 mut/mut ear skin had a lower abundance of transcripts encoding targets of IL-17A, including the antimicrobial peptides β-defensin 3 and β-defensin 4, as well as the neutrophil chemoattractant CXCL2, than did wild-type ear skin (Fig. 6d) . Moreover, we observed less migration of Ly6G + CD11b + neutrophils to extracts of ear skin prepared from Sox13 mut/mut mice than to those from wild-type mice, all collected after 3 d of imiquimod treatment (Fig. 6f) . These findings suggested that cytokine production by skin-resident V γ 4 + γδT17 cells contributed to the magnitude of skin inflammation in the early phases of imiquimod-induced psoriasis-like dermatitis.
Dermal gdT17 cells migrate from skin to draining lymph nodes It is known that γδT17 cells are present in both the dermis and skindraining lymph nodes, although whether dermal γδT17 cells migrate to draining lymph nodes has not been assessed. We used transgenic mice expressing the green-to-red photoconvertible KikGR protein 29 to track the migration of cells. Similar to findings obtained with transgenic mice that express the photoconvertible Kaede protein 30 , exposure of ear skin for 10 min to 415-nm violet light was sufficient to convert ear skin cells from green to red (Fig. 7a) . Photoconversion was specific to ear skin cells, as we detected few KikGR-red + cells in the draining lymph nodes or blood immediately after photoconversion (Supplementary Fig. 6a ). Exposure to violet light did not lead to measurable inflammation, as assessed by the induction of transcripts encoding IL-1β (Supplementary Fig. 6b ), consistent with published findings [30] [31] [32] . Analysis of draining cervical lymph nodes 24 h later showed that 1-5% of CCR6 + γδT17 cells were KikGR-red + (Fig. 7b) , which suggested that dermal γδT17 cells migrated to draining lymph nodes at a low rate in the steady state. A similar fraction of lymph node MHCII hi CD11c + dendritic cells were KikGR-red + (refs. 30,32; Supplementary Fig. 6c ). We next treated ear skin with imiquimod or control cream daily for 1, 3 or 5 d and photoconverted the ear skin 24 h before analysis. The number of KikGR-red + CCR6 + γδT17 cells in the draining lymph nodes was unchanged at days 1 and 3, but increased slightly at day 5; this change was accompanied by a substantial (approximately tenfold) increase in the number of KikGR-red + CCR6 − γδ T cells at day 5 (Fig. 7c,d) . These CCR6 − γδ T cells may have corresponded to activated γδT17 cells that had downregulated CCR6 expression 33 (data not shown). As expected, we also observed an increase in the number of KikGR-red + dendritic cells in draining lymph nodes of imiquimod-treated mice at days 3 and 5 ( Supplementary Fig. 6d ). These findings established that there was more flux of γδ T cells from skin to draining lymph nodes after treatment with imiquimod.
Lymph node V g 4 + gdT17 cells home to inflamed skin Analysis of draining lymph nodes in wild-type mice after 5 d of imiquimod treatment showed substantial and selective expansion of the V γ 4 + subset of γδT17 cells (Fig. 8a,b) , many of which were CCR6 lo or CCR6 − (data not shown). The blood also had more V γ 4 + γδT17 cells (Fig. 8c) . No expansion of the V γ 4 + γδT17 cell subset occurred 
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A r t i c l e s in Sox13 mut/mut mice (Fig. 8a,b) . The V γ 4 − subset of γδT17 cells expanded modestly and only in proportion to the greater cellularity of the draining lymph nodes (Fig. 8a,b) . Notably, the increase in V γ 4 + γδT17 cells in the lymph nodes was specific to cells expressing V δ 4 (Fig. 8d) . In ear skin, we observed a substantial increase in V γ 4 + V δ 4 + γδT17 cells 2 d later, at day 7 of imiquimod treatment (Fig. 8d) .
To determine whether the expanded population of V γ 4 + γδT17 cells in the lymph nodes was able to migrate to inflamed skin, we collected cells from the draining lymph nodes of wild-type CD45.2 + mice after 5 or 7 d of imiquimod treatment and intravenously transferred the cells into Sox13 mut/mut CD45.1 + recipient mice that had been treated for 2 d with imiquimod. At 3 h after transfer, we collected ear skin, draining lymph nodes and blood for analysis of CD45.2 + cells. We observed considerable enrichment for V γ 4 + γδ T cells in inflamed ear skin, where they constituted ~25% of donor-derived cells (compared with their frequency (~1%) in the donor population), whereas their frequency in blood and draining cervical lymph nodes (<2%) was similar to the input frequency (Fig. 8e) .
Given the ability of V γ 4 + γδT17 cells to efficiently home to inflamed skin, we sought to determine whether psoriasis-like changes could be promoted by the transfer of lymph node cells from wild-type mice at day 5 of imiquimod treatment. We transferred 3 × 10 7 to 5 × 10 7 total lymph node cells into Sox13 mut/mut recipient mice that had been treated for 1 d with imiquimod and analyzed the recipients 2 d later. Donor V γ 4 + γδ T cells accumulated in the treated ear skin at frequencies even greater than those observed at 3 h after transfer (Fig. 8e,f) . Whereas the frequency of donor-derived cells corresponding to V γ 4 + γδ T cells in the blood and draining lymph nodes was low (<3%), V γ 4 + γδ T cells constituted the majority of donor-derived cells in the ear skin (66-85%; Fig. 8f) . Moreover, nearly all IL-17 + donorderived cells in the ear skin were V γ 4 + γδT17 cells (Fig. 8f) , which suggested that among IL-17-committed donor cells, V γ 4 + γδT17 cells selectively accumulated in inflamed skin. The reason for the greater frequency of donor V γ 4 + γδT17 cells in inflamed skin collected at 2 d after transfer than at 3 h after transfer may have been due to continued homing from the blood and population expansion or enhanced survival of the cells. Notably, the ear skin of Sox13 mut/mut mice that received wild-type cells had a twofold greater frequency of neutrophils than did the ear skin of Sox13 mut/mut mice that did not receive donor cells (Fig. 8g) . The recipients of wild-type cells had a greater abundance of transcripts encoding IL-17A and IL-17F, as well as those encoding the IL-17A targets CXCL2 and β-defensin 3, than did mice that did not receive cells (Fig. 8h) . The selective accumulation of V γ 4 + γδT17 cells among IL-17-committed cells favored the view that Sox13-dependent V γ 4 + γδT17 cells promoted dermatitis, although we cannot rule out the possibility of contributions from other donor lymph node cells. Together these data were consistent with a model in which the V γ 4 + γδT17 cell subset expanded in the draining lymph nodes, recirculated to inflamed skin and promoted IL-17-driven inflammatory changes.
DISCUSSION
Here we have described a selective deficiency in V γ 4 + γδT17 cells in the NCI and Tac substrains of CD45.1 + congenic C57BL/6 mice due to a spontaneous mutation in Sox13. We found that Sox13-dependent cells, most probably V γ 4 + γδT17 cells, contributed to psoriasis-like dermatitis, as Sox13 mut/mut skin had diminished activity of the IL-17 pathway and skin inflammation. Moreover, the V γ 4 + γδT17 cell subset underwent substantial expansion in draining lymph nodes and homed to inflamed skin, where they promoted inflammatory changes. Although our identification of a spontaneous Sox13 mutation in two widely used substrains establishes a need for caution in interpreting IL-17 responses npg in these mice, the ready availability of Sox13 mut/mut mice should facilitate analysis of the contributions of γδT17 cells to a range of immune responses. In addition to being associated with psoriasis-like dermatitis, γδT17 cells have been linked to autoimmune encephalomyelitis 1,2 , collagen-induced arthritis 3 and a variety of bacterial infections 1, 7, 8 . We anticipate that cytokine production by resident V γ 4 + γδT17 cells, as well as their population expansion, recirculation and tissue-specific homing, will be found to be involved in many of these responses. Sox13 expression is upregulated early during γδ T cell development and, on the basis of studies of embryonic Sox13 −/− mice, has been suggested to promote commitment to the γδ T lineage 15, 17 . Our analysis of adult Sox13 mut/mut mice, which had a normal frequency of CCR6 − γδ T cells, has suggested that Sox13 may not be essential for commitment to the γδ T lineage. Accordingly, published studies have shown that some developing γδ T cell subsets have low Sox13 expression 16, 34, 35 . However, the frameshift mutation in Sox13 may not completely inactivate Sox13, and we therefore cannot exclude the possibility that residual activity of a splice variant or truncated protein may sustain the development of some Sox13-dependent cells. In contrast to Sox13 mut/mut mice, Sox13 −/− mice suffer severe postnatal growth defects 15 . The basis for the difference in postnatal viability is unclear but could be due to residual Sox13 activity in Sox13 mut/mut mice or to off-target mutations in mice derived from Sox13 −/− embryonic stem cells. Future comparisons of these and further Sox13-mutant mouse lines should resolve these issues.
How Sox13 promotes the development of V γ 4 + γδT17 cells is unclear, but this may involve interaction with TCF-1, an high-mobilitygroup transcription factor involved in the development of αβ T cells 15, 36 . TCF-1 represses Il17a and inhibits T H 17 differentiation 37, 38 , which suggests that Sox13 may antagonize TCF-1-mediated repression of Il17a in γδ T cells. Moreover, published work suggests that Sox13 may promote the differentiation of γδT17 cells by upregulating IL-7Rα expression 16 . However, those observations do not explain the more substantial involvement we observed for Sox13 in the development of V γ 4 + γδT17 cells than in that of V γ 4 − γδT17 cells. Further work will be needed to determine the target genes of Sox13 that are essential for the development of V γ 4 + γδT17 cells and to discern how Sox13 contributes to the maturation of V γ 4 − γδT17 cells.
Precisely when V γ 4 + γδT17 cells develop in the thymus has not been clearly defined, as γδT17 cells have been reported in the embryonic, neonatal and adult thymus 14, 16, 18, 26, 39 . Here we found that immature V γ 4 + γδT17 cells were present in the thymus at birth and subsequently matured into CD24 lo CCR6 + cells, which suggests that V γ 4 + γδT17 cells develop in the early postnatal thymus. In contrast, mature CD24 lo CCR6 + V γ 4 − γδT17 cells were already present in the thymus at birth, which suggests that V γ 4 − γδT17 cells develop in an earlier wave. Given that γδT17 cells include mainly V γ 4 + and V γ 6 + subsets 14 , most V γ 4 − γδT17 cells probably correspond to V γ 6 + γδT17 cells, which develop mainly in the embryonic thymus subsequent to V γ 5 + dendritic epidermal γδ T cell precursor cells 11, 12, 14, 16 .
CCR6 + γδT17 cells are present in the mouse dermis, and skindraining lymph nodes show enrichment for these cells. Our findings obtained with KikGR mice suggested that CCR6 + γδT17 cells were able to migrate from the skin to draining lymph nodes in the steady state. We used violet light to photoconvert KikGR, which, in contrast to ultraviolet light, is not thought to cause inflammatory changes [30] [31] [32] . However, we cannot rule out the possibility that exposure to violet light may have certain immunomodulatory effects that affect cell migration. Nonetheless, the ability of dermal γδ T cells to migrate to draining lymph nodes is consistent with the possibility that the lymph node population may be at least in part skin derived, although some of this population may also be maintained as a separate pool. Analysis of skin-draining lymph in cattle, a species rich in γδ T cells, has demonstrated substantial flux of γδ T cells from the skin to the draining lymph nodes 40 . Treatment with imiquimod promoted more migration of γδ T cells from the skin to draining lymph nodes, with many of the migrating cells being CCR6 − . Given that CCL20 expression is higher in inflamed skin 41 , this raises the possibility that downregulation of CCR6 expression promotes the egress of activated γδT17 cells from the skin.
Published studies have reported a greater abundance of γδT17 cells in the skin and draining lymph nodes after treatment with imiquimod 4, 6 . Here we observed selective accumulation of V γ 4 + V δ 4 + γδT17 cells in the draining lymph nodes at day 5, probably due mostly to proliferation in the lymph nodes, as many of the cells were blasting and rapidly incorporated the thymidine analog BrdU (data not shown). Expansion of the V γ 4 + V δ 4 + γδT17 cell subset in draining lymph nodes after subcutaneous injection of complete Freund's adjuvant has also been reported 3 . What promotes expansion of the V γ 4 + V δ 4 + subset of γδT17 cells is unclear but may include induction of both inflammatory cytokines (such as IL-1β and IL-23) and their cognate TCR ligand. IL-7 may also contribute to this, as it is sufficient to promote the proliferation of γδT17 cells in lymph nodes 27 .
The paradigm of population expansion in lymph nodes followed by circulation and selective homing to inflamed tissue has been central to the understanding of αβ T cell responses 42 . Our findings add to limited published data 3, 43 by demonstrating that γδT17 cells may also follow this paradigm, as they underwent massive population expansion in the lymph nodes and were able to efficiently home to inflamed skin. Clinical use of topical imiquimod for the treatment of cutaneous pre-cancers can lead to psoriasis exacerbations, including those at distal sites 44 . Published work has identified circulating, skinhoming CLA + CCR6 + γδ T cells in humans that can be recruited to perturbed skin and are more abundant in psoriasis lesions 45 . Thus, we are tempted to speculate that local imiquimod treatment in humans may promote the population expansion and recirculation of activated, skin-homing, IL-17-committed lymphocytes that are then available for recruitment to distal skin sites.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession code. Sequence Read Archive: SRP019001. located within 3 cM of Ptprc, 77 were ruled out, as they were reported in the US National Institutes of Health database of single-nucleotide polymorphisms (http://www.ncbi.nlm.nih.gov/snp) or Sanger Institute Mouse Genomes Project database (http://www.sanger.ac.uk/cgi-bin/modelorgs/mousegenomes/snps.pl) for the A/J, DBA2, FVB.N, NOD or PWD strain, which have V γ 4 + CCR6 + γδT17 cells (Supplementary Fig. 3a,b, Supplementary Table 1) ; one Ptprc variant present in Ptprc a (CD45.1) alleles was ruled out 50 (Supplementary  Table 1) ; six variants were ruled out based on their presence in B6.SJL/Jax mice by Sanger sequencing; and one Cfhr2 coding variant was not confirmed in B6.SJL/NCI mice by Sanger sequencing and was excluded (Supplementary Table 2 ). The single coding variant that remained was a frameshift mutation in Sox13 (Fig. 3a,b and Supplementary Table 2) .
